Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib.

Next Previous
Trial Profile

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms STIM-2

Most Recent Events

  • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 12 Mar 2018 Status changed from active, no longer recruiting to completed.
  • 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top